Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

PepGen Inc. - Common Stock (NQ:PEPG)

1.410 +0.150 (+11.90%)
Streaming Delayed Price Updated: 11:54 AM EDT, May 8, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about PepGen Inc. - Common Stock

< Previous 1 2 3 Next >
PepGen Reports First Quarter 2025 Financial Results and Recent Corporate Highlights
From PepGen Inc.
Via Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc - PEPG
From Pomerantz LLP
Via GlobeNewswire
PepGen to Present at the 24th Annual Needham Virtual Healthcare Conference
From PepGen Inc.
Via Business Wire
PepGen Announces Appointment of Two New Directors to its Board
From PepGen Inc.
Via Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc - PEPG
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc - PEPG
From Pomerantz LLP
Via GlobeNewswire
PepGen Announces Presentations at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference
From PepGen Inc.
Via Business Wire
PepGen to Participate in Upcoming Investor Conferences
From PepGen Inc.
Via Business Wire
PepGen Announces Update to Phase 2 CONNECT2-EDO51 Study in Patients with DMD
From PepGen Inc.
Via Business Wire
PepGen Reports Fourth Quarter and Year-End 2024 Financial Results and Recent Corporate Highlights
From PepGen Inc.
Via Business Wire
PepGen Announces Positive Initial Results, Including Robust Splicing Correction, from Ongoing FREEDOM-DM1 Trial in Patients with DM1
From PepGen Inc.
Via Business Wire
PepGen Announces CONNECT Program Updates
From PepGen Inc.
Via Business Wire
PepGen Announces Clinical Hold in the U.S. on IND Application to Initiate CONNECT2-EDO51 Phase 2 Study of PGN-EDO51 for Duchenne Muscular Dystrophy
From PepGen Inc.
Via Business Wire
PepGen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Senior Vice President, Clinical Development
From PepGen Inc.
Via Business Wire
PepGen Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights
From PepGen Inc.
Via Business Wire
PepGen to Participate in Upcoming Investor Conferences
From PepGen Inc.
Via Business Wire
PepGen Announces Presentations at the 29th Annual Congress of the World Muscle Society
From PepGen Inc.
Via Business Wire
Capricor Therapeutics Is Up Over 100%, Could Rise Even Higher
Capricor Therapeutics Inc. (NASDAQ: CAPR) is a biotechnology firm focused on developing cell and exosome-based treatments for rare diseases like iomyopathy 
Via MarketBeat
Exposures Product Safety
PepGen Announces Christopher Ashton, PhD, to Retire from its Board of Directors
From PepGen Inc.
Via Business Wire
PepGen Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Executive Vice President, Research & Development
From PepGen Inc.
Via Business Wire
PepGen Appoints Paul Streck, M.D., MBA, as Executive Vice President, Head of Research & Development
From PepGen Inc.
Via Business Wire
PepGen Inc. (PEPG) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
PepGen Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights
From PepGen Inc.
Via Business Wire
PepGen Inc. (PEPG) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
PEPG Investors Have Opportunity to Join PepGen Inc. Securities Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.